Bristol-Myers Squibb Company logo
Bristol-Myers Squibb Company (BMY)
Compare

Bristol-Myers Squibb Company (BMY) EV/EBIT Ratio: 12.14x

Is Bristol-Myers Squibb Company’s EV/EBIT ratio high or low?

Bristol-Myers Squibb Company's EV/EBIT ratio of 12.14x is 36% below its 5-year average of 18.89x, near the low end of its 5-year range (9.29x–36.51x).

As of Thursday, June 11, 2026. 6.92% above its 12-month average of 11.35x.

BMY EV/EBIT Ratio Chart

BMY EV/EBIT Ratio
12.14x-6.97% 1Y
Zoom

BMY Average EV/EBIT Ratio Chart

BMY Current vs Average EV/EBIT Ratio Chart

BMY EV/EBIT Ratio Metrics

EV/EBIT RATIO

12.14x

EV/EBIT RATIO AVG TTM

11.35x

EV/EBIT RATIO AVG 3Y

15.41x

EV/EBIT RATIO AVG 5Y

18.89x

EV/EBIT RATIO AVG 10Y

22.21x

EV/EBIT RATIO AVG 15Y

25.48x

EV/EBIT RATIO AVG 20Y

22.54x

CURRENT VS TTM AVG

+6.92%

CURRENT VS 3Y AVG

-21.20%

CURRENT VS 5Y AVG

-35.74%

CURRENT VS 10Y AVG

-45.33%

CURRENT VS 15Y AVG

-52.36%

CURRENT VS 20Y AVG

-46.13%

BMY Competitors' EV/EBIT Ratio

NAMEMARKET CAPEV/EBIT RATIOTTM3Y5Y
Bristol-Myers Squibb Company (BMY)$116.13B12.14x11.35x15.41x18.89x
Vertex Pharmaceuticals Incorporated (VRTX)$110.59B22.87x26.41x24.92x21.76x
Danaher Corporation (DHR)$126.39B27.62x30.65x32.50x29.68x
CVS Health Corporation (CVS)$126.70B32.55x28.87x19.89x18.76x
Medtronic plc (MDT)$102.72B19.23x23.68x24.37x26.81x
Intuitive Surgical, Inc. (ISRG)$144.79B45.37x63.25x73.01x67.77x
Elevance Health Inc. (ELV)$86.47B14.59x11.84x13.42x14.42x
Pfizer Inc. (PFE)$149.61B14.37x12.24x29.84x23.37x
Cigna Corporation (CI)$77.92B10.72x11.17x12.56x13.06x
Abbott Laboratories (ABT)$155.75B22.39x27.94x30.32x27.86x

Bristol-Myers Squibb Company EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Bristol-Myers Squibb Company EV/EBIT Ratio FAQ

What is the EV/EBIT ratio for Bristol-Myers Squibb Company (BMY)?
The EV/EBIT ratio for BMY stock is 12.14x.
Is Bristol-Myers Squibb Company's EV/EBIT ratio high or low?
Bristol-Myers Squibb Company's EV/EBIT ratio of 12.14x is 36% below its 5-year average of 18.89x, near the low end of its 5-year range (9.29x–36.51x).
What is the TTM average EV/EBIT ratio for Bristol-Myers Squibb Company (BMY)?
The TTM average EV/EBIT ratio for BMY stock is 11.35x.
What is the 3Y average EV/EBIT ratio for Bristol-Myers Squibb Company (BMY)?
The 3Y average EV/EBIT ratio for BMY stock is 15.41x.
What is the 5Y average EV/EBIT ratio for Bristol-Myers Squibb Company (BMY)?
The 5Y average EV/EBIT ratio for BMY stock is 18.89x.
What is the 10Y average EV/EBIT ratio for Bristol-Myers Squibb Company (BMY)?
The 10Y average EV/EBIT ratio for BMY stock is 22.21x.
What is the 15Y average EV/EBIT ratio for Bristol-Myers Squibb Company (BMY)?
The 15Y average EV/EBIT ratio for BMY stock is 25.48x.
What is the 20Y average EV/EBIT ratio for Bristol-Myers Squibb Company (BMY)?
The 20Y average EV/EBIT ratio for BMY stock is 22.54x.

Bristol-Myers Squibb Company EV/EBIT Ratio History

DATEEV/EBIT RATIO
2026-06-1112.14x
2026-06-1011.93x
2026-06-0912.08x
2026-06-0811.93x
2026-06-0512.21x
2026-06-0412.10x
2026-06-0311.79x
2026-06-0211.74x
2026-06-0111.83x
2026-05-2912.19x
2026-05-2812.15x
2026-05-2712.25x
2026-05-2612.33x
2026-05-2212.57x
2026-05-2112.58x
2026-05-2012.41x
2026-05-1912.38x
2026-05-1812.21x
2026-05-1512.16x
2026-05-1412.12x
2026-05-1312.06x
2026-05-1212.07x
2026-05-1111.94x
2026-05-0812.02x
2026-05-0712.04x
2026-05-0612.09x
2026-05-0512.15x
2026-05-0412.22x
2026-05-0112.36x
2026-04-3012.75x
2026-04-2912.17x
2026-04-2812.27x
2026-04-2712.20x
2026-04-2412.35x
2026-04-2312.40x
2026-04-2212.36x
2026-04-2112.46x
2026-04-2012.41x
2026-04-1712.58x
2026-04-1612.39x
2026-04-1512.22x
2026-04-1412.25x
2026-04-1312.24x
2026-04-1012.33x
2026-04-0912.47x
2026-04-0812.43x
2026-04-0712.18x
2026-04-0612.45x
2026-04-0212.49x
2026-04-0112.83x
2026-03-3112.66x
2026-03-3012.51x
2026-03-2712.32x
2026-03-2612.46x
2026-03-2512.38x
2026-03-2412.13x
2026-03-2312.07x
2026-03-2012.15x
2026-03-1912.25x
2026-03-1812.45x
2026-03-1712.51x
2026-03-1612.51x
2026-03-1312.41x
2026-03-1212.39x
2026-03-1112.55x
2026-03-1012.58x
2026-03-0912.66x
2026-03-0612.60x
2026-03-0512.67x
2026-03-0412.93x
2026-03-0312.75x
2026-03-0212.93x
2026-02-2712.94x
2026-02-2612.73x
2026-02-2512.76x
2026-02-2412.81x
2026-02-2312.76x
2026-02-2012.66x
2026-02-1912.60x
2026-02-1812.51x
2026-02-1712.61x
2026-02-1312.67x
2026-02-1212.53x
2026-02-1112.54x
2026-02-1011.54x
2026-02-0911.53x
2026-02-0611.71x
2026-02-0511.34x
2026-02-0411.06x
2026-02-0310.82x
2026-02-0210.81x
2026-01-3010.68x
2026-01-2910.57x
2026-01-2810.62x
2026-01-2710.76x
2026-01-2610.62x
2026-01-2310.62x
2026-01-2210.67x
2026-01-2110.60x
2026-01-2010.56x
2026-01-1610.71x
2026-01-1510.91x
2026-01-1410.97x
2026-01-1310.81x
2026-01-1210.79x
2026-01-0910.80x
2026-01-0810.81x
2026-01-0710.93x
2026-01-0610.59x
2026-01-0510.39x
2026-01-0210.45x
2025-12-3110.52x
2025-12-3010.56x
2025-12-2910.54x
2025-12-2610.62x
2025-12-2410.63x
2025-12-2310.57x
2025-12-2210.63x
2025-12-1910.56x
2025-12-1810.43x
2025-12-1710.46x
2025-12-1610.56x
2025-12-1510.57x
2025-12-1210.29x
2025-12-1110.11x
2025-12-1010.12x
2025-12-0910.03x
2025-12-0810.18x
2025-12-0510.25x
2025-12-0410.23x
2025-12-0310.08x
2025-12-029.68x
2025-12-019.82x
2025-11-289.82x
2025-11-269.83x
2025-11-259.80x
2025-11-249.61x
2025-11-219.38x
2025-11-209.34x
2025-11-199.32x
2025-11-189.50x
2025-11-179.47x
2025-11-149.44x
2025-11-139.74x
2025-11-129.80x
2025-11-119.75x
2025-11-109.53x
2025-11-079.45x
2025-11-069.44x
2025-11-059.42x
2025-11-049.29x
2025-11-039.35x
2025-10-319.36x
2025-10-309.29x
2025-10-2910.05x
2025-10-2810.08x
2025-10-2710.18x
2025-10-2410.25x
2025-10-2310.25x
2025-10-2210.34x
2025-10-2110.36x
2025-10-2010.21x
2025-10-1710.21x
2025-10-1610.18x
2025-10-1510.21x
2025-10-1410.24x
2025-10-1310.20x
2025-10-1010.27x
2025-10-0910.39x
2025-10-0810.36x
2025-10-0710.38x
2025-10-0610.46x
2025-10-0310.51x
2025-10-0210.56x
2025-10-0110.84x
2025-09-3010.46x
2025-09-2910.30x
2025-09-2610.30x
2025-09-2510.18x
2025-09-2410.30x
2025-09-2310.42x
2025-09-2210.44x
2025-09-1910.44x
2025-09-1810.54x
2025-09-1710.63x
2025-09-1610.66x
2025-09-1510.66x
2025-09-1210.64x
2025-09-1110.85x
2025-09-1010.79x
2025-09-0910.80x
2025-09-0810.72x
2025-09-0510.79x
2025-09-0410.72x
2025-09-0310.85x
2025-09-0210.83x
2025-08-2910.80x
2025-08-2810.75x
2025-08-2710.87x
2025-08-2610.80x
2025-08-2510.79x
2025-08-2210.92x
2025-08-2111.00x
2025-08-2010.97x
2025-08-1910.99x
2025-08-1810.96x
2025-08-1511.00x
2025-08-1410.90x
2025-08-1310.91x
2025-08-1210.69x
2025-08-1110.59x
2025-08-0810.59x
2025-08-0710.50x
2025-08-0610.41x
2025-08-0510.58x
2025-08-0410.50x
2025-08-0110.31x
2025-07-3110.16x
2025-07-3012.27x
2025-07-2912.43x
2025-07-2812.55x
2025-07-2512.73x
2025-07-2412.82x
2025-07-2312.83x
2025-07-2212.65x
2025-07-2112.40x
2025-07-1812.53x
2025-07-1712.66x
2025-07-1612.49x
2025-07-1512.35x
2025-07-1412.52x
2025-07-1112.43x
2025-07-1012.74x
2025-07-0912.58x
2025-07-0812.47x
2025-07-0712.36x
2025-07-0312.44x
2025-07-0212.58x
2025-07-0112.55x
2025-06-3012.33x
2025-06-2712.34x
2025-06-2612.39x
2025-06-2512.40x
2025-06-2412.46x
2025-06-2312.44x
2025-06-2012.43x
2025-06-1812.43x
2025-06-1712.50x
2025-06-1612.77x
2025-06-1312.97x
2025-06-1213.15x
2025-06-1113.05x
2025-06-1013.01x
2025-06-0912.83x
2025-06-0612.72x
2025-06-0512.62x
2025-06-0412.64x
2025-06-0312.66x
2025-06-0212.79x
2025-05-3012.70x

Showing the most recent 260 of 5,032 data points. The chart above shows the full history.

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.

Princeton, NJ
34,100 employees
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Christopher S. Boerner